TERTp mutation screening using digital droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma
<i>TERTp</i> mutations, specific for tumor DNA of glioblastomas, are determined by ddPCR in both the tumor sample and the CFDNA of the blood plasma, which indicates the transition of tumor DNA into the circulating (ctDNA) and that the ctDNA passes through the blood-brain barrier (BBB) of patients. The possibility of non-invasive molecular genetic characterization of tumor lesions of the CNS in blood plasma of patients with glioblastoma has been tested. The obtained results' analysis shows the need to optimize the extraction of CFDNA and modify the testing system to improve the method's effectiveness.
Authors
- Tsimur N. Hasanau (ORCID: https://orcid.org/0000-0003-3093-5723)
- Eduard Pisarev (ORCID: https://orcid.org/0000-0002-5764-3977)
- Svetlana Pavlova (ORCID: https://orcid.org/0000-0002-9595-9358)
- Maria I. Zvereva (ORCID: https://orcid.org/0000-0002-7432-1574)
- Galina Valerievna Pavlova (ORCID: https://orcid.org/0000-0002-6885-6601)
- Igor Pronin (ORCID: https://orcid.org/0000-0002-4480-0275)
- Sergey Drozd (ORCID: https://orcid.org/0000-0001-7496-4310)
- Alexander V. Sergeev (ORCID: https://orcid.org/0000-0002-0479-6910)
- D. Yu. Panteleev (ORCID: https://orcid.org/0000-0003-4271-6915)
Institutions
- Lomonosov Moscow State University (RU)
- Burdenko Neurosurgery Institute (RU)
- Moscow State University (TJ)
- Institute of Higher Nervous Activity and Neurophysiology (RU)
Publication Details
- Journal
- Burdenko s Journal of Neurosurgery
- Published
- 2025-10-16
- DOI
- https://doi.org/10.17116/neiro20258905187
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00